Needham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Mereo BioPharma Group (NASDAQ:MREO) and maintained a $6 price target.
May 16, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Mereo BioPharma Group and maintained a $6 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $6 price target by a reputable analyst suggests positive sentiment and confidence in Mereo BioPharma Group's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100